The inhibitor of apoptosis protein family has been characterized over the past 5 years, initially in baculovirus and more recently in metazoans. The IAPs are a widely expressed gene family of apoptotic inhibitors from both phylogenic and physiologic points of view. The diversity of triggers against which the IAPs suppress apoptosis is greater than that observed for any other family of apoptotic inhibitors including the bcl-2 family. The central mechanisms of IAP apoptotic suppression appear to be through direct caspase and pro-caspase inhibition (primarily caspase 3 and 7) and modulation of and by the transcription factor NF-kB. Although evidence for a direct oncogenic role for the IAPs has yet to be delineated, a number of lines of evidence point towards this class of protein playing a role in oncogenesis. The strongest evidence for IAP involvement in cancer is seen in the IAP called survivin. Although not observed in adult dierentiated tissue, survivin is present in most transformed cell lines and cancers tested to date. Survivin has been shown to inhibit caspase directly and apoptosis in general, moreover survivin protein levels correlate inversely with 5 year survival rates in colorectal cancer. Recent data has also implicated survivin in cell cycle control. The second line of evidence for IAP involvement in cancer comes from their emerging role as mediators and regulators of the anti-apoptotic activity of v-Rel and NF-kB transcription factor families. The IAPs have been shown to be induced by NF-kB or v-Rel in multiple cell lines and conversely, HIAP1 and HIAP2 have been shown to activate NF-kB possibly forming a positive feed-back loop. Overall a picture consistent with an IAP role in tumour progression rather than tumour initiation is emerging making the IAPs an attractive therapeutic target.
The ®rst Inhibitor of Apoptosis (IAP) proteins were identi®ed in 1993 and 1994 in the baculoviruses Cydia pomonella granulosis virus (CpGV) and Orgyia pseudotsugata nuclear polyhedrosis virus (OpMNPV) by the laboratory of Lois Miller (Crook et al., 1993; Birnbaum et al., 1994) . The Miller lab utilized an assay in which infection by a mutant strain of a third baculovirus, Autographa californica nuclear polyhedrosis virus (AcMNPV) results in an unconstrained host lepidopteran SF-21 cell apoptosis. (The natural host cell apoptotic response to viral infection is usually eectively suppressed by the infecting baculovirus). Employing this assay, the CpGV and OpMNPV genomes were screened for loci which would suppress this cell death, resulting in the identi®cation of founding members of a new class of anti-apoptotic genes encoding Cp-IAP and Op-IAP, two proteins which share both homology and the ability to block apoptosis by a wide number of apoptotic triggers (Tables 1, 2 and 5).
BIR and RING Zn ®nger domains
There exists in the baculoviral IAPs two de®ning motifs. The ®rst of these is the BIR (for Baculoviral Inhibitor of apoptosis Repeat) domain; a pair of these comprise the amino terminal half of the viral IAPs. The 80 amino acid BIR domain contains a possible serine/threonine phosphorylation site (RX 2 ST/F) followed 17 residues downstream by an invariant glycine and then DX 3 CX 2 C and HX 6 C consensus sequences ( Figure 1 ). These latter arrays are also likely metal coordination sites although this remains to be formally documented; the physical structure of the BIR has not yet been documented but is clearly a priority. The importance of the non-conserved residues in the BIR domain is re¯ected in the fact that the Ac-IAP found in a third AcMNPV baculovirus, although containing the conserved BIR residues, is inactive with regard to apoptotic inhibition (Birnbaum et al., 1994) .
The second de®ning motif found in the baculoviral IAPs is the COOH terminus RING Zn ®nger (for Really Interesting New Gene, Freemont et al., 1991) containing a CX 2 CX N CXHX 2 -3 CX 2 CXMCX 2 C motif (metal coordinating sites underlined, Figure 2 ). NMR based structural analysis has revealed the RING ®nger to assume a spherical cross brace structure with two Zn coordination sites identi®ed; one comprised of the ®rst and third cluster of metal binding residues and the second coordination de®ned by the second and fourth metal binding residue clusters (Barlow et al., 1994) . The RING Zn ®nger has been seen in nearly 100 proteins, is usually localized at the amino terminus of a protein and has been shown to be involved in DNA and protein interactions (Borden and Freemont, 1996) . The lack of conservation in the non-cys/his residues between various RING ®ngers is in keeping with the diverse functions postulated for these domains. The presence of the RING Zn ®nger appears to be critical to the baculoviral IAP anti-apoptotic function while it is dispensable for some (but not all) cellular IAP apoptotic inhibition (Table 5) .
Non-viral IAPs
The initial baculoviral IAP discovery was followed in 1995 by the identi®cation of a series of metazoan IAPs, the ®rst of these being the NAIP gene. NAIP is alone in the BIR containing proteins insofar as it has three BIRs but no RING Zn ®nger (The A and I are interposed to distinguish it from the more classic IAPs which contain not only the BIR domain but the RING Zn ®nger as well). This gene was found by virtue of it's absence from the majority of infants with the most severe form of the pediatric neurodegenerative disorder known as spinal muscular atrophy (SMA, Roy et al., 1995) . This autosomal recessive condition is caused by Roy et al., 1995; Chen et al., 1998; mNAIP1-6 , mouse NAIP-1 through 6 (AF007769) Yaraghi et al., 1998 ; NAIP-rs 1 through 6, NAIP related sequence 1 (U66324), 2 (U66325), 3 (U66326), 4 (U66327), 5 (U66328), 6 (U66329) Scharf et al., 1996 ; rNAIP, Rat NAIP (partial cDNA) Korneluk et al., (unpublished); HIAP1, human IAP1 (U45878) Liston et al., 1996 ; cIAP2, cellular IAP2 (L49432) Rothe et al., 1995 ; MIHC, mammalian IAP homolog C (U37546) Uren et al., 1996;  hITA, human inhibitor of T-cell apoptosis, Nicholl et al., 1996 ; MIAP1, mouse IAP1 (U88908) Liston et al., 1997; RIAP1, rat IAP1 Holcik et al., (unpublished) ; PIAP, porcine IAP (U79142) Stehlik et al., 1998b ; ITA, inhibitor of T-cell apoptosis (U27466) Digby et al., 1996; ch-IAP1, chicken a severe loss of motor neurons which results in fatal accid paralysis (Dubowitz, 1995) . While the contiguous SMN gene has been found to be causative of SMA , the tissue expression of NAIP (Xu et al., 1997a) combined with its strong in vitro (Liston et al., 1996) and in vivo (Xu et al., 1997b) neuroprotective eect make it a likely candidate for modi®cation of the SMA phenotype. It is postulated that motor neurons missing NAIP withstand the low cellular levels of SMN protein poorly and dying earlier than they would have otherwise resulting in more severe disease (MacKenzie, 1998).
In the period since the cloning of NAIP, four additional BIR containing human genes have been identi®ed. Three of these (XIAP, HIAP1 and HIAP2) contain NH2 BIR domains and COOH RING ®nger domains as is the case with the baculoviral IAPs (Rothe et al., 1995; Liston et al., 1996; Duckett et al., 1996; Uren et al., 1996) . There are two chief features which distinguish these four human IAPs from the viral IAPs; they have three (instead of two) BIR domains and the section between BIR and RING ®nger is longer than that seen in the baculovirus, and contains a CARD (for caspase recruitment domain, Hofmann et al., 1997; see Figure 3 ) motif in the case of HIAP1 and HIAP2 ( Table 2 ). The CARD motif, which is predicted to consist of six alpha helices, is commonly found in proteins involved in apoptotic signalling, including the caspases (e.g. caspase 1) as well as some of the IAPs. A fourth human gene, survivin contains a solitary BIR domain and shows strongest upregulation in tumours (Ambrosini et al., 1997) . A potential sixth human IAP expressed solely in testes has been identi®ed (Figures 1 and 2 ). The TIAP (not to be confused with murine survivin also called TIAP) is a transcribed processed pseudogene; whether the TIAP transcript is also translated is currently unknown (Lagace and Korneluk, personal communication). In addition to these genes, porcine, chicken, Drosophila, rat, murine, yeast and nematode IAPs have all been found (Table 1) . These genes contain a number of permutations and combinations of BIR, RING Zn Figure 1 Alignment of IAP BIR domains. Alignment of all vertebrate IAP BIR amino acid sequences, plus some other nonvertebrate member sequences, was performed using the PILEUP program of GCG (Genetics Computer Group, Wisconsin). The exact BIR repeat for those IAPs with multiple repeats is listed in order of their appearance in the protein from N-terminus to Cterminus as 1 ± 3 (indicated by the ®nal hyphenated number after the name). The start position for each repeat is indicated for each protein on the left-hand side of the sequence. Please refer to Table 1 for abbreviated names and accession numbers. Alignment of identical residues are highlighted in black while conservative residues are grey. The consensus sequence given is for amino acids that are present in over 70% of the proteins shown and is indicated in upper case if present in 100% of proteins Table 2 ). Many of the vertebrate IAPs have had their chromosomal localization determined (Table 3) . One of the more intriguing proteins is a large murine ubiquitin conjugating enzyme, BRUCE, which contains both a BIR domain and a UBC motif, possibly re¯ecting an intersection of apoptotic and ubiquitination pathways (Hauser et al., 1998) .
The two IAPs in Drosophila were identi®ed by means of screening for suppressors of Reaper induced ocular cell death (Hay et al., 1995) . This work was the ®rst to point to the BIR domains as being the main arbiters of apoptotic inhibition in metazoan systems; (a truncated IAP containing solely the BIR domains showed enhanced eye cell rescue). It was also the ®rst (and still only) to unequivocally show a phenotype associated with loss of IAP function; this consisted of branching defects in the aristae located on Drosophila antennae and an increase of Reaper induced death.
IAP interacting proteins and mechanisms of action
As is frequently the case with in vitro recapitulation of biological systems, IAP mediated anti-apoptosis appears to be a highly trigger and cell type speci®c phenomenon; what is observed in one system may not hold true for another. Nonetheless, the conservation of both sequence and function between baculoviral and cellular IAPs suggest strongly that they interact with conserved components of the apoptotic mechanism, an observation supported by the ability of baculoviral IAPs to inhibit mammalian cell death from a number of triggers Dorstyn and Kumar, 1997; Hawkins et al., 1996 Hawkins et al., , 1998  Table 5 ). Despite this apparent conservation of biological eect, a mechanistic divergence is apparent on close examination. This is seen most clearly in the requirement for the full length baculoviral IAP in virtually all arthropod cell death paradigms studied while the BIR domains alone are sucient for apoptotic inhibition in many systems using the cellular IAPs.
IAPs interact with and inhibit the caspases
In broad terms it appears that the majority of IAPs inhibit the cysteine proteases known as caspases. While there has been some con¯icting data, all metazoan IAPs tested to date have been shown by at least one group to inhibit this class of pro-apoptotic proteases (Table 4) .
Speci®cally, IAPs have been shown to directly inhibit activated caspase 3 and 7 (Deveraux et al., 1997; Roy et al., 1997; Tamm et al., in press). The caspases exist as inactive pro-caspases which require proteolytic activation; in this regard the IAPs have also been shown to inhibit the activation of pro-caspase 9 . There is also some evidence for an indirect inhibition of caspase 1 (ICE) and caspase 2 by baculoviral IAPs (Hawkins et al., 1998) . Moreover, despite the presence of the CARD domain in some IAPs, this inhibitory activity maps to the BIR domains with, in at least one case, a single XIAP BIR being both sucient and necessary for the observed inhibition (Takahashi et al., 1998) . The case for arthropod caspase inhibition is less clear for baculoviral systems, the number of caspases to test are far fewer than those identi®ed in mammalian systems. In contrast to mammalian systems, no eect on activated insect caspase by Op-IAP is observed although inhibition of the activation of pro-caspases has been documented (Manji et al., 1997; Seshagiri and Miller 1997) .
Non-caspase inhibitory mechanisms of the IAPs
There appears to exist with the IAPs the counterintuitive (but not unprecedented as has been seen with Bcl-2) situation wherein a single protein possesses biochemically distinct mechanisms directed to the same end. Thus IAPs can also inhibit apoptosis through non-caspase mechanisms. The evidence for non caspase interactions is stronger for Drosophila IAPs; although baculoviral and human IAPs have also been shown to interact with and inhibit the proapoptotic Drosophila proteins Hid, Reaper, Grim and Doom (Hay et al., 1995 ; Vucic et al., 1997a,b; Harvey et al., 1997a,b; Seshagiri and Miller, 1997) . Mammalian homologs of these
proteins have yet to be identi®ed. A number of studies have shown that the mammalian IAPs inhibit apoptosis by non-caspase interactions chie¯y involving NF-kB and in one case, JNK1. Two of the ®rst cellular IAPs (HIAP1 and HIAP2) identi®ed were isolated by virtue of their interaction with the TNFa receptor associated factor 2 (TRAF2; Rothe et al., 1995) . Although no clear cytoprotection devolving from the interaction could be documented in this study, it raised the possibility that IAP apoptotic suppression might be mediated in part through modulation of the TNFa signal transduction pathway. In this regard, TNFR1 and 2 can trigger both apoptotic and anti-apoptotic responses in the cell; the latter being mediated chie¯y by the transcription factor NF-kB (Rothe et al., 1995; Wang et al., 1996; Beg and Baltimore, 1996; Van Antwerp et al., 1996) . TNFa has been shown in Jurkat cells to upregulate HIAP1 through NF-kB, conversely HIAP1 activates NF-kB. Moreover, in one study, HIAP1 protection from TNFa killing was found to be dependent upon the presence of NF-kB underlining the centrality of this mechanism to IAP protection in Jurkat cells (Chu et al., 1997) . A recent analysis of primary endothelial cells revealed a signi®cant upregulation of HIAP1, HIAP2 and XIAP following exposure to TNFa (Stehlik et al., 1998a) . This stimulation appears to be downstream of NF-kB given the fact that overexpression of the NF-kB inhibitor, IkB, totally suppressed IAP induction and sensitizes cells to apoptotic stimuli and, conversely, overexpression of XIAP reconstitutes cytoprotection, abrogating the IkB inhibition. Similarly, a dierential display analysis of porcine aortic endothelial cells revealed an inducible porcine IAP with 73.9% amino acid homology to HIAP1 (Stehlik et al., 1998b) . Speci®cally, LPS, TNFa Wang et al., 1998 Deveraux et al., 1998 Takahashi et al., 1998 Rothe et al., 1995 Uren et al., 1996; Roy et al., 1997; Hawkins et al., 1998 Rothe et al., 1995 Uren et al., 1996; Shu et al., 1996; Duckett et al., 1998; Roy et al., 1997; Hawkins et al., 1998 Chu et al., 1997 Wang et al., 1998 ; **Tanner (personal communication) Sanna et al., 1998 McCarthy and Vucic et al., 1997a , 1998 Hay et al., 1995 Vucic et al., 1997a Vucic et al., ,b, 1998 Seshagiri and Miller, 1997 Harvey et al., 1997a Harvey et al., 1997a ,b Oeda et al., 1998 Crook et al., 1993 Clem and Miller, 1994 McLachlin and Miller, 1997 Clem and Miller, 1994 Clem and Miller, 1994 continued and IL-Ib were found to upregulate this gene and this induction was suppressed by IkB suggesting a direct role for NF-kB stimulation of these cells. A more detailed discussion of the role of NF-kB in IAP function is given in part B.
Other IAP interactions
A number of other non-caspase mechanisms of apoptotic inhibition have been proposed including a recent co-transfection study of cos-7 and 293 cells which revealed an XIAP mediated inhibition of caspase 1 by a selective activation of the c-Jun Nterminal kinase (Sanna et al., 1998) . This activation, which mapped to the BIR domains and the contiguous spacer region, was essential to the observed apoptotic suppression. A recent demonstration of the interaction of HIAP1 (but not HIAP2) with the kinase RIP2 in a MCF7 breast carcinoma cell line raises the possibility that the inhibition of this pro-apoptotic kinase directly contributes to the suppression of apoptosis . In contrast to previous work showing the cytoprotective eect of NF-kB, RIP2 is both proapoptotic and an activator of NF-kB underlining the importance of cellular context in IAP function. More recently, the single BIR containing survivin has been shown to be expressed in cell cycle dependent manner, apparently interacting with spindle microtubules. Disruption both of this binding, which is mediated by the survivin carboxyl terminal coiled coil domain, and mutation of the BIR domain abrogates the apoptotic inhibition. This suggests that the inhibition of caspases in situ on the spindle apparatus is a prerequisite for the most eective apoptotic suppression at least in this model (Li et al., in press ). The Drosophila IAPs have been demonstrated to interact with Thick Veins, a type I serine/threonine kinase receptor for Decapentaplegic (a member of the BMP/ TGF superfamily; Oeda et al., 1998) . Interestingly, this interaction is mediated by the RING ®nger of DIAP1, the only function attributed to this domain so far. Furthermore, XIAP has just been shown to interact with TAB1 and BMP receptors in humans (Yamaguchi et al., in press ). TAB1 binds the TGF-activated kinase 1, TAK1, which is a member of the MAPKKK family. Overexpression of XIAP stimulated ventralization in Xenopus embryos in a TAB1-TAK1-dependent manner. Moreover, an interaction between XIAP and BMP (for bone morphogenic protein) receptor in mammalian cells, mediated through the RING ®nger, has been demonstrated (Yamaguchi et al., in press) . A more detailed list of all IAP interactions is given in Table 4 .
The IAPs protect against a broad spectrum of apoptotic triggers
IAPs have shown a remarkable ability to block apoptosis induced by a wide spectrum of non-related apoptotic triggers. The signi®cant majority of apoptotic triggers are blocked by at least one IAP (Table 5) with very few exceptions. They block, for example, a broader spectrum of triggers than does Bcl-2 possibly re¯ecting a site of activity further downstream than that of the Bcl-2 family (see Table 5 for references).
IAPs protect against apoptosis induced by TNFa, Fas ligand and transducers of the TNF receptor superfamily (RIP, RIP2/RICK/CARDIAK, FADD, v-Rel), pro-apoptotic members of the Bcl-2 family (BIK, BAK, BAX) and cytochrome C, chemotherapeutic drugs (etoposide, cisplatin, taxol, actinomycin D, Adriamycin), ionizing or UV radiation, oxidative stress (menadione, 6-OH dopamine), ischemia, potassium withdrawal, viral infections (baculovirus, Sindbis) or viral proteins (E1A, IE1), growth factor withdrawal (serum, IL-3), caspases (1, 2, 3, 7, 8 and SF caspase), Drosophila death proteins (Reaper, GRIM, HID, DOOM) and several other triggers that do not fall into one of the above categories. The only exceptions to this list are glutamate excitotoxicity (which induces a necrotic form of cell death), staurosporine which may kill by a secondary mechanism not involving caspase-3 or DNA cleavage (Krohn et al., 1998) , and vincristine or nocodazole (Li et al., in press ). However, only survivin has been tested in the latter case; it remains to be seen if other IAPs can protect against microtubule disruption caused by drugs such as vincristine and nocodazole. It is also noteworthy that FADD induced cell death was only partially protected by IAPs even though IAPs can protect well against TNFa or Fas ligand induced cell death, implying that the signal from overexpressed FADD is stronger than that observed by Fas activation alone. Increased IAP expression also correlates with increased tumour survival (see Part B) and inhibition of follicular atresia in maturing ovarian follicles Johnson et al., 1998) . HIAP1 is also induced by dexamethasone and interferon gamma in a lung carcinoma cell line under circumstances of dexamethasone induced protection against IFNg and Fas mediated apoptosis (Wen et al., 1997) .
Part B. Emerging role of the IAPs in cancer
Increased apoptosis resistance promotes tumour development and resistance to drug and radiation therapy
Apoptosis is the chief means by which radio-and chemotherapy modalities kill cancer cells. The discovery that the bcl-2 oncogene, characteristic of follicular lymphomas bearing the t(14;18) translocation, is an inhibitor of apoptosis has revolutionized our thinking of tumour initiation and progression, identifying apoptotic inhibition as a mechanism of cancer formation, progression and resistance to therapy. The bcl-2 family of proteins has grown dramatically to include not only anti-apoptotic members, but also pro- apoptotic members such as Bax. Bax is a candidate tumour suppressor and is regulated by p53 (Selvakumaran et al., 1994; Yin et al., 1997) ; loss of p53 activity results in loss of Bax activity. Bax is also mutated in colon cancer possibly playing a role in tumour progression (Rampino et al., 1997) . A theme is now emerging that inhibition of apoptosis is a common property for cancer cells, increasing their survival and facilitating their escape from immune surveillance and cytotoxic therapies. Another example of this is the increased expression of FLIP in melanoma leading to an increased resistance to Fas mediated cell killing (Irmler et al., 1997) . Similarly, v-Rel prevents apoptosis in transformed lymphoid cells (Zong et al., 1997) . The transforming activity of v-Rel is dependent on its gene regulatory activities and is thought to be mediated, in part, by its anti-apoptotic eects.
Many and probably most apoptotic processes are ultimately channeled through the eector proteases, caspases, which are another potential source of cancer resistance. This has been demonstrated experimentally by introducing caspase inhibiting viral proteins, such as p35 or CrmA into cancer cells and observing increased resistance to cell killing by chemotherapeutics (Antoku et al., 1997; Qi et al., 1997; Barge et al., 1997; Los et al., 1997; Srikanth and Kraft, 1998) . Data correlating lack of caspase activity with increased cellular apoptotic resistance is also emerging (Eichholtz-Wirth et al., 1997; Martinez-Lorenzo et al., 1998; Fulda et al., 1998) . Recently, the baculoviral caspase inhibitor p35 has been shown to have transforming activity in cooperation with IGF-1 signalling (Resnico et al., 1998) . These ®ndings set the stage for a potential oncogenic role for other inhibitors of apoptosis. The IAPs are prime candidates in this regard because of their caspase inhibitory activity and TNF and Fas receptor modulatory activities. To date, the two strongest pieces of evidence for IAP involvement in cancer are (1) the cancer speci®c expression of an IAP called survivin which is not normally expressed in dierentiated tissue, and (2) the emerging role of the IAPs in the anti-apoptotic eect mediated through the NF-kB transcription factor.
The fetal IAP, survivin, is expressed in most cancers and correlates with shorter disease survival Survivin is the smallest IAP cloned to date, consisting only of 142 amino acids, with only a single N-terminal BIR domain (Ambrosini et al., 1997) . Survivin shows markedly dierent tissue expression when compared with the other IAPs. Data from our laboratory shows that XIAP, HIAP1 and HIAP2 are comparatively ubiquitously expressed, while NAIP is more restricted (e.g. brain, liver, macrophage). In contrast, survivin is expressed fetally and not in adult dierentiated tissue (Ambrosini et al., 1997; Adida et al., 1998a) . Remarkably, survivin is expressed in most cancers tested (lung, colon, breast, prostate, pancreas, highgrade lymphomas, neuroblastomas, gastric) with the exception of low-grade lymphomas (Ambrosini et al., 1997; Adida et al., 1998b; Lu et al., 1998; Kawasaki et al., in press) (Table 6) .
Although the argument for a role of survivin in cancer progression or drug resistance is correlative so far, the protein has been shown to protect against apoptosis induced by IL-3 withdrawal in IL-3 dependent pre-B cells (Ambrosini et al., 1997) , against taxol induced apoptosis in NIH3T3 cells (Li et al., in press) and against Fas, Bax and etoposide in 293 cells (Tamm et al., in press) . Moreover, the use of a survivin antisense results in increased apoptosis and inhibits cell proliferation Li et al., in press) . Survivin has recently been demonstrated to also inhibit caspase-3 activity directly (Tamm et al., in press; Maier, Nicholson, Roy, and MacKenzie, unpublished) . Immunohistochemical analysis of biopsy material has revealed that 60% of stage 3 ± 4 neuroblastomas are survivin positive (Adida et al., 1998b) , while 53% of colon cancers (all stages) (Kawasaki et al., in press) and 35% of gastric cancers (all stages) are positive ) (see Table 6 ). Survivin correlates with worsening stage or unfavourable histology for neuroblastoma (Adida et al., 1998b) , and with decreased apoptotic index in gastric cancer or colon cancer (Kawasaki et al., in press ). More importantly, survivin expression is associated with shortened 5-year disease survival rates (a 10% decrease compared to survivin negative patients, although not statistically signi®cant). Survivin expression also correlates with decreased apoptotic indices and bcl-2 expression in colon cancer, moreover patient 5-year disease survival rates are 20% lower in the patients with a low apoptotic index (statistically signi®cant). Although the apoptotic index is most likely the result of several genes in addition to bcl-2 and survivin, it is nonetheless noteworthy that survivin expression correlates with the apoptotic index in two dierent cancers and that this has been shown to be clinically relevant for colon cancer.
Recently, a possible link between cell cycle progression and apoptosis has emerged. Survivin has been shown to associate with mitotic spindles through a coiled-coil interaction involving the C-terminal end of survivin (Li et al., in press ). Interestingly, survivin shows cell cycle speci®c expression in G2/M which is mediated by G1 transcriptional repressor elements in the survivin promoter. This suggests speci®c dual control of the mitotic spindle checkpoint and apoptosis by survivin (Li et al., in press ). Survivin protects against taxol (a microtubule stabilizer) induced cell death but fails to protect against microtubule disruption (e.g. vincristine and nocodazole) induced cell death. It will be important to see if other IAPs associate with microtubules and if they can protect against vincristine or nocodazole induced cell death.
IAPs as mediators and regulators of the anti apoptotic activity of v-Rel and NF-kB family members
The role the Rel/NF-kB/IkB family members in cancer is becoming increasingly evident (reviewed in Gilmore et al., 1996; Luque and Gelinas, 1997) . Besides the well known transforming properties of v-Rel in birds, or bcl-3 (mutant IkB) in human chronic lymphocytic leukemias/lymphomas, ampli®cations and rearrangements involving Rel/NF-kB members occur in many solid and haematological malignancies (Gilmore et al., 1996; Luque and Gelinas, 1997) . It is also becoming more evident that NF-kB exerts anti-apoptotic eects, inhibiting TNF induced cell death (Beg and Baltimore, 1996; Van Antwerp et al., 1996 , 1998 and protecting cells from ionizing radiation and chemotherapeutic drugs. NF-kB activation is required to suppress apoptosis induced by oncogenic ras (Mayo et al., 1997) and to aid in Bcr-Abl-mediated transformation (Reuther et al., 1998) . Constitutive activation of NFkB is seen during progression of breast cancer (Nakshatri et al., 1997; Sovak et al., 1997) and is required for proliferation and survival of Hodgkin's disease tumour cells (Bargou et al., 1997) . Interestingly, inhibition of NF-kB activity attenuates apoptosis resistance in lymphoid cells (Jeremias et al., 1998) and potentiates TNF and cancer therapy-induced apoptosis in a ®brosarcoma cell line (Wang et al., 1996) . Therefore, the identi®cation of anti-apoptotic genes or survival factor genes induced by NF-kB is of paramount interest. Recently, HIAP1 and PIAP or ch-IAP1 have been shown to be induced by NF-kB or vRel, respectively, in multiple cell lines (Chu et al., 1997; Wang et al., 1998; Stehlik et al., 1998a,b; You et al., 1997) . There is also evidence for HIAP2 induction by NF-kB is some systems Stehlik et al., 1998a) and for XIAP only in endothelial cells (Stehlik et al., 1998a) . CD40L is also able to induce HIAP1, presumably through the CD40 receptor, another member of the TNF receptor superfamily, which is well known to provide survival signals in Bcells (Craxton et al., 1998) . Inhibition of IAP induction by IkB dominant negatives lead to cell death and over expression of these IAPs leads to cell survival in these systems. This was elegantly tested in the chicken spleen cells using temperature sensitive mutants of v-Rel to control the induction of exogenous ch-IAP1 (You et al., 1997) . IAPs may not be the only anti-apoptotic genes induced by NF-kB. It has recently been demonstrated that at least three other anti-apoptosis genes are induced by NF-kB or NF-kB-activating agents: they are A20 (Song et al., 1996) , MnSOD (Wong and Goeddel, 1988; Wong et al., 1989; Jones et al., 1997; Mattson et al., 1997; Keller et al., 1998) and an alternate splice product of an immediate early gene, IEX-1L (Wu et al., 1998) . It is also important to note that NF-kB can induce survival factors in lymphoid cells such as IL-6, and IL-2-receptors. Some or all of these gene products likely determine the cells fate depending on the cell type, the gene program that is activated and the various environmental stimuli. The IAPs may be the predominant anti-apoptotic factor induced by NF-kB but this remains to be clearly proven. Of special interest here is the fact that HIAP1 and HIAP2 are able to activate NF-kB (Chu et al., 1997; Wang et al., 1998) and XIAP may also activate NF-kB under some circumstances (Tanner, personal communication) and thus may lead to a positive feedback loop whereby the HIAPs through their interaction with TRAF-1, TRAF-2 or RIP2/RICK/ CARDIAK can potentiate the activation of NF-kB which in turn leads to increased HIAP1 gene expression reinforcing the anti-apoptotic eects of HIAP1. It is interesting to note the zinc ®nger apoptosis inhibitor A20 which is induced by NF-kB is, in contrast to the HIAPs, a negative regulator of NF-kB activation (Song et al., 1996) , as is MnSOD (Manna et al., 1998) . Also relevant to this discussion is the possible induction of IAPs through NF-kB following EBV infection. It is postulated that the host cell surface late antigen LMP1 acts as a constitutively active receptor molecule triggering NF-kB activation, responsible in part for B-cell transformation (Kaye et al., 1996; Izumi et al., 1997; Gires et al., 1997) . This may explain the high level of HIAP1 expression seen in the Reed-Sternberg cells found in Hodgkin's disease; LMP1 is present in Reed-Sternberg cells in 70% of such malignancies (Messineo et al., 1998) . LMP1 also induces A20 (Fries et al., 1996) and bcl-2 (Henderson et al., 1991) .
It is therefore interesting to speculate that the induction of IAPs by NF-kB activation is responsible in part or whole for the anti-apoptotic eects of NFkB which lead to tumour cell survival, B-cell transformation, radiation and drug resistance. Inhibition of HIAP function, such as through a knock-out mouse model, will demonstrate the protective eects of IAPs in immune function and cancer and distinguish the IAPs eects from other NF-kB inducible genes.
Future trends
Much work still needs to be done to establish the role of IAPs in cancer. However, new and exciting data are coming forth supporting just such a role for the IAPs; we believe it is likely that IAPs other than survivin and HIAP1 will likely be demonstrated to have a role in cancer. The IAPs may not be the initiating event in cancer as no obvious chromosomal translocations are associated with their genomic loci (Table 3) but they are likely to play a role in disease progression and resistance to therapy, and therefore represent new therapeutic targets for cancer treatment.
